tbuckley/cabot-search huggingface dataset:
Maintenance of Weight Loss After Initiation of Nutrition Training
Authors: Corrine I. Voils, Maren K. Olsen, Jennifer M. Gierisch, Megan A. McVay, Janet M. Grubber, Leslie Gaillard, Jamiyla Bolton, Matthew L. Maciejewski, Elizabeth Strawbridge, William S. Yancy
Journal: Annals of Internal Medicine (2017)

Background: Weight regain after successful weight loss interventions is common. Objective: To establish the efficacy of a weight loss maintenance program compared with usual care in obese adults. Design: 2-group, parallel, randomized trial stratified by initial weight loss (<10 kg vs. ≥10 kg), conducted from 20 August 2012 to 18 December 2015. Outcome assessors were blinded to treatment assignment. (ClinicalTrials.gov: NCT01357551) Setting: 3 primary care clinics at the Veterans Affairs Medical Center in Durham and Raleigh, North Carolina. Patients: Obese outpatients (body mass index ≥30 kg/m2) who lost 4 kg or more of body weight during a 16-week, group-based weight loss program. Intervention: The maintenance intervention, delivered primarily by telephone, addressed satisfaction with outcomes, relapse-prevention planning, self-monitoring, and social support. Usual care involved no contact except for study measurements. Measurements: Primary outcome was mean weight regain at week 56. Secondary outcomes included self-reported caloric intake, walking, and moderate physical activity. Results: Of 504 patients in the initial program, 222 lost at least 4 kg of body weight and were randomly assigned to maintenance (n = 110) or usual care (n = 112). Retention was 85%. Most patients were middle-aged white men. Mean weight loss during initiation was 7.2 kg (SD, 3.1); mean weight at randomization was 103.6 kg (SD, 20.4). Estimated mean weight regain was statistically significantly lower in the intervention (0.75 kg) than the usual care (2.36 kg) group (estimated mean difference, 1.60 kg [95% CI, 0.07 to 3.13 kg]; P = 0.040). No statistically significant differences in secondary outcomes were seen at 56 weeks. No adverse events directly attributable to the intervention were observed. Limitations: Results may not generalize to other settings or populations. Dietary intake and physical activity were self-reported. Duration was limited to 56 weeks. Conclusion: An intervention focused on maintenance-specific strategies and delivered in a resource-conserving way modestly slowed the rate of weight regain in obese adults. Primary Funding Source: Veterans Affairs Health Services Research and Development Service.
Erratum: Akirins are highly conserved nuclear proteins required for NF-κB-dependent gene expression in drosophila and mice
Authors: Akira Goto, Kazufumi Matsushita, Viola Gesellchen, Laure El Chamy, David Kuttenkeuler, Osamu Takeuchi, Jules A Hoffmann, Shizuo Akira, Michael Boutros, Jean-Marc Reichhart
Journal: Nature Immunology (2008)
Selective Androgen Receptor Modulator in a Patient With Hormone-Positive Metastatic Breast Cancer
Authors: Namratha Vontela, Vamsi Koduri, Lee S. Schwartzberg, Gregory A. Vidal
Journal: Journal of the National Comprehensive Cancer Network (2017)

Androgen receptors (ARs) are highly coexpressed in estrogen receptor (ER)–positive breast cancers. Their role in breast tumorigenesis has been postulated, but the mechanism is not yet well-characterized. Steroidal androgens were previously used as an anticancer strategy but fell out of favor because of toxicity and the discovery of alternative therapies. Recent attempts to modulate androgen pathway signaling have focused on AR inhibitors. This report discusses a case using a well-tolerated selective AR modulator to treat a highly pretreated patient with ER-positive breast cancer, which resulted in a durable partial response.
Preclinical Evaluation of a Potent Anti-Bcma CD3 Bispecific Molecule for the Treatment of Multiple Myeloma
Authors: Siler H Panowski, Tracy Kuo, Amy Chen, Tao Geng, Thomas J Van Blarcom, Kevin Lindquist, Wei Chen, Javier Chaparro-Riggers, Barbra Sasu
Journal: Blood (2016)
Abstract ES8-1: ES8-1 Managing the aftermath of estrogen deprivation in survivors
Authors: AH Partridge
Journal: Cancer Research (2017)

Abstract Endocrine therapy is the most important systemic treatment for women with hormone receptor-positive breast cancer, resulting in substantial risk reduction and improvements in survival. Yet, the strategies to reduce or block estrogen including ovarian suppression or ablation, aromatase inhibition or tamoxifen can all lead to symptoms and long-term toxicities associated with estrogen deprivation. The effect of long-term estrogen deprivation on bone, heart and brain health may lead to substantial morbidity and should be considered when making treatment decisions and managed in follow-up. However, even less serious daily symptoms including hot flashes, mood changes, insomnia, weight gain, vaginal dryness and sexual dysfunction can lead to profound negative long term effects on a patient and her relationships. Thus even these more minor concerns should be considered and managed proactively for patient overall health and well-being. For serious co-morbidity risks, attention to optimizing risk factors and monitoring when appropriate (e.g., DEXA scan) is prudent. For symptom management, it is generally recommended that survivors forgo estrogen replacement therapy although sometimes a low dose, short course of replacement therapy is necessary. Otherwise, strategies include a multi-prong approach focusing not only on improving particular symptoms, but also on mitigating the downstream effects and emotional impact. Evidence-based strategies for management of vaginal dryness, hot flashes and other problems will be discussed Citation Format: Partridge AH. ES8-1 Managing the aftermath of estrogen deprivation in survivors [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr ES8-1.
Decreased Incidence of Clonal Evolution to Myelodysplastic Syndrome/Acute Myeloid Leukemia with Monosomy 7 in Children with Aplastic Anemia Following Reduced Use of G-CSF.
Authors: Yoshiyuki Takahashi, Akira Ohara, Ryoji Kobayashi, Hiromasa Yabe, Masahiro Tsuchida, Hideo Mugishima, Akira Morimoto, Shoichi Ohga, Fumio Bessho, Ichiro Tsukimoto, Tatsutoshi Nakahata, Seiji Kojima
Journal: Blood (2007)
An Electrochemical Strategy using Multifunctional Nanoconjugates for Efficient Simultaneous Detection of <i>Escherichia coli </i>O157: H7 and <i>Vibrio cholerae</i> O1
Authors: Yan Li, Ya Xiong, Lichao Fang, Lili Jiang, Hui Huang, Jun Deng, Wenbin Liang, Junsong Zheng
Journal: Theranostics (2017)

The rapid and accurate quantification of the pathogenic bacteria is extremely critical to decrease the bacterial infections in all areas related to health and safety.We have developed an electrochemical strategy for simultaneous ultrasensitive detection of E. coli O157:H7 and Vibrio cholerae O1.This approach was based on the specific immune recognition of different pathogenic bacteria by multifunctional nanoconjugates and subsequent signal amplification.By employing the proposed biosensor, the concentrations of these pathogenic bacteria could be established on a single interface in a single run with improved sensitivity and accuracy.The successful approach of the simultaneous detection and quantification of two bacteria by an electrochemical biosensor demonstrated here could be readily expanded for the estimation of a variety of other pathogenic bacteria, proteins, and nucleotides.Because of their high sensitivity, electrochemical biosensors may represent a new avenue for early diagnosis of diseases.
Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: A pooled analysis of four randomized trials
Authors: C. Mazouni, F. André, K. Broglio, L. Pusztai, G. N. Hortobagyi
Journal: Journal of Clinical Oncology (2009)

1046 Background:Differences in the efficacy of various chemotherapies in patients with estrogen receptor (ER) positive metastatic breast cancer are not well understood. In the present study, we assessed the efficacy of docetaxel in patients with metastatic breast cancer according to ER expression.Methods: The efficacy of docetaxel on response rates and progression-free survival were analyzed according to ER expression in four randomized trials that included a total of 1,631 patients. Odds-ratio for tumor response was estimated with logistic regression and hazard ratio for progression-free survival was estimated with Cox proportional hazards models. Results: ER expression was assessable in 1,037 patients included in these trials (64%). ER was expressed in 601 tumors (58%). Overall, docetaxel was associated with an increased response rate (odds ratio: 2.66, 95% CI: 1.83 to 3.87) and decreased hazard of disease progression (hazard ratio: 0.85, 95% CI: 0.73 to 0.97) compared to non-docetaxel containing therapy. Docetaxel was associated with similar improvement in response rate both in patients with ER-positive (odds ratio: 2.90, 95% CI: 1.72 to 4.87) and ER-negative disease (odds ratio: 2.55, 95% CI: 1.44 to 4.51). Among all ER-positive patients, tumor response rate was 31.1% among patients who did not receive docetaxel and 46.8% among patients who did receive docetaxel. Decreased hazard of disease progression due to docetaxel was also similar in ER-positive (HR: 0.82, 95% CI: 0.67–1.00) and ER-negative cancers (HR: 0.86, 95% CI: 0.70–1.07), but these results were heterogeneous among trials. The effect of docetaxel was not different in ER-positive and ER-negative disease, both in terms of response rates and progression-free survival (interaction test, p = 0.77 and p = 0.93). Conclusions: Docetaxel increases response rates and decreases the risk of disease-progression in a statistically similar extent both in patients with ER-positive and ER-negative metastatic breast cancer. No significant financial relationships to disclose.
A Phase 2 Study to Evaluate the Efficacy and Safety of Simtuzumab in Adult Subjects with Primary, Post Polycythemia Vera (PV) or Post Essential Thrombocythemia (ET) Myelofibrosis
Authors: Srdan Verstovsek, Michael R. Savona, Ruben A. Mesa, Stephen Oh, Hua Dong, Dung Thai, Jason Gotlib
Journal: Blood (2015)
Single-Cell Profiling of an In Vitro Model of Human Interneuron Development Reveals Temporal Dynamics of Cell Type Production and Maturation
Authors: Jennie L. Close, Zizhen Yao, Boaz P. Levi, Jeremy A. Miller, Trygve E. Bakken, Vilas Menon, Jonathan T. Ting, Abigail Wall, Anne-Rachel Krostag, Elliot R. Thomsen, Angel M. Nelson, John K. Mich, Rebecca D. Hodge, Soraya I. Shehata, Ian A. Glass, Susan Bort, Nadiya V. Shapovalova, N. Kiet Ngo, Joshua S. Grimley, John W. Phillips, Carol L. Thompson, Sharad Ramanathan, Ed Lein
Journal: Neuron (2017)
Irish GPs support wider use of naloxone to treat opiate addiction
Authors: Susan Mayor
Journal: BMJ (2017)

Two thirds of GPs in Ireland support planned initiatives to provide wider availability of naloxone in the community for treating opiate addiction and overdose, a survey has found.1

More than 200 deaths due to opiate overdose occur each year in Ireland, one of the highest rates in Europe. Naloxone is an effective opiate antagonist that can treat opiate overdose. “Take home” naloxone schemes, in which patients considered at risk …
PP05. CHARACTERISATION OF DAXX IN THE DEPOSITION OF H3.3 IN PAEDIATRIC GLIOMA
Authors: Mr Mickey Lewis, Dr Thomas Jacques, Dr Darren Hargrave, Dr John Anderson, Prof Paolo Salomoni, Dr David Michod
Journal: Neuro-Oncology (2017)

Brain tumours are currently the leading cause of cancer-related mortality and morbidity in children. The cause and the pathobiology of childhood brain tumours is not fully understood. Interestingly the histone variant H3.3 and its chaperones DAXX and ATRX have recently been found to be mutated in a variety of cancers and particularly in paediatric glioblastoma, thus suggesting that defects of the chromatin architecture underlie paediatric glioblastoma pathogenesis. We aimed to describe the regulation of H3.3 deposition in paediatric glioblastoma and the involvement of DAXX expression and phosphorylation. We analysed DAXX phosphorylation level and expression of other histone chaperones in five different paediatric glioblastoma cell lines. We found that the phosphorylsated form of DAXX is mostly localised outside the areas of heterochtomatin in comparison to DAXX. Utilising CRISPR technology, cell models were created where endogenous DAXX was downregulated and overexpressed phospho-mutant forms of DAXX was introduced. The phospho-mutant clones produced a certain phenotype with irregular cell morphology and nuclear structure possibly due to chromosomal instability. Changes in telomere length were quantified between the cell models which showed little variance. However differences in cell cycle length were measured in between the different cell models by EdU staining. In summary, our data shows that DAXX expression is key to survival in peadriatic cell lines, that modulating DAXX phosphorylation is fundamental to its function and therefore its H3.3 chaperone activity, which has the potential to be a new target for paediatric glioblastoma treatment.
A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities.
Authors: Thomas S. Lin, Margaret S. Lucas, Nyla A. Heerema, Jennifer J. Matkovich, Mollie E. Moran, Carolyn Cheney, David M. Lucas, Donn C. Young, Michael A. Caligiuri, Michael R. Grever, John C. Byrd
Journal: Blood (2006)
Molecular Mechanism behind the Synergistic Activity of Proteasome Inhibition and PRC2 Inhibition in the Treatment of Multiple Myeloma
Authors: Ola Rizq, Naoya Mimura, Motohiko Oshima, Atsunori Saraya, Shuhei Koide, Yuko Kato, Kazumasa Aoyama, Yaeko Nakajima-Takagi, Changshan Wang, Anqi Ma, Jian Jin, Tohru Iseki, Chiaki Nakaseko, Atsushi Iwama
Journal: Blood (2016)
Inflammation and metabolic cardiomyopathy
Authors: Kazuhiko Nishida, Kinya Otsu
Journal: Cardiovascular Research (2017)

Excessive feeding is associated with an increase in the incidence of chronic metabolic diseases, such as obesity, insulin resistance, and type 2 diabetes. Metabolic disturbance induces chronic low-grade inflammation in metabolically-important organs, such as the liver and adipose tissue. Many of the inflammatory signalling pathways are directly triggered by nutrients. The pro-inflammatory mediators in adipocytes and macrophages infiltrating adipose tissue promote both local and systemic pro-inflammatory status. Metabolic cardiomyopathy is a chronic metabolic disease characterized by structural and functional alterations and interstitial fibrosis without coronary artery disease or hypertension. In the early stage of metabolic cardiomyopathy, metabolic disturbance is not accompanied by substantial changes in myocardial structure and cardiac function. However, metabolic disturbance induces subcellular low-grade inflammation in the heart, and in turn, subcellular component abnormalities, such as oxidative stress, mitochondrial dysfunction, endoplasmic reticulum stress, and impaired calcium handling, leading to impaired myocardial relaxation. In the advanced stage, the vicious cycle of subcellular component abnormalities, inflammatory cell infiltration, and neurohumoral activation induces cardiomyocyte injury and death, and cardiac fibrosis, resulting in impairment of both diastolic and systolic functions. This review discusses some recent advances in understanding involvement of inflammation in metabolic cardiomyopathy.
Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population
Authors: Nadine Hein, Donald P. Cameron, Katherine M. Hannan, Nhu-Y N. Nguyen, Chun Yew Fong, Jirawas Sornkom, Meaghan Wall, Megan Pavy, Carleen Cullinane, Jeannine Diesch, Jennifer R. Devlin, Amee J. George, Elaine Sanij, Jaclyn Quin, Gretchen Poortinga, Inge Verbrugge, Adele Baker, Denis Drygin, Simon J. Harrison, James D. Rozario, Jason A. Powell, Stuart M. Pitson, Johannes Zuber, Ricky W. Johnstone, Mark A. Dawson, Mark A. Guthridge, Andrew Wei, Grant A. McArthur, Richard B. Pearson, Ross D. Hannan
Journal: Blood (2017)
Stem Cell-like Megakaryocyte Progenitors As Driving Forces of IFN-Induced Emergency Megakaryopooesis
Authors: Simon Haas, Jenny Hansson, Daniel Klimmeck, Dirk Loeffler, Lars Velten, Hannah Uckelmann, Stephan Wurzer, Áine M. Prendergast, Alexandra Schnell, Klaus Hexel, Rachel Santarella-Mellwig, Sandra Blaszkiewicz, Andrea Kuck, Hartmut Geiger, Michael D. Milsom, Lars M Steinmetz, Timm Schroeder, Andreas Trumpp, Jeroen Krijgsveld, Marieke A. G. Essers
Journal: Blood (2015)
In Search of a “Magic Pill” for Medication Nonadherence
Authors: Ian M. Kronish, Nathalie Moise
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Autoimmunity against a defective ribosomal insulin gene product in type 1 diabetes
Authors: Maria J L Kracht, Menno van Lummel, Tatjana Nikolic, Antoinette M Joosten, Sandra Laban, Arno R van der Slik, Peter A van Veelen, Françoise Carlotti, Eelco J P de Koning, Rob C Hoeben, Arnaud Zaldumbide, Bart O Roep
Journal: Nature Medicine (2017)
The histone methyltransferase Suv39h2 contributes to nonalcoholic steatohepatitis in mice
Authors: Zhiwen Fan, Luyang Li, Min Li, Xinjian Zhang, Chenzhi Hao, Liming Yu, Sheng Zeng, Huihui Xu, Mingming Fang, Aiguo Shen, Thomas Jenuwein, Yong Xu
Journal: Hepatology (2017)

Uncontrolled inflammatory response highlights the central theme of nonalcoholic steatohepatitis (NASH), a growing global pandemic. Hepatocytes and macrophages represent two major sources of hepatic inflammation during NASH pathogenesis, contributing to excessive synthesis of proinflammatory mediators. The epigenetic mechanism that accounts for the activation of hepatocytes and macrophages in this process remains obscure. Here, we report that compared to wild‐type littermates, mice with a deficiency in the histone H3K9 methyltransferase suppressor of variegation 39 homolog 2 (Suv39h2, knockout) exhibited a less severe form of NASH induced by feeding with a high‐fat, high‐carbohydrate diet. Pro‐NASH stimuli increased Suv39h2 expression in cell culture, in mice, and in human livers. In hepatocytes, Suv39h2 bound to the Sirt1 gene promoter and repressed Sirt1 transcription. Suv39h2 deficiency normalized Sirt1 expression, allowing nuclear factor kappa B/p65 to become hypoacetylated and thus dampening nuclear factor kappa B–dependent transcription of proinflammatory mediators. In macrophages, Suv39h2‐mediated repression of peroxisome proliferator–activated receptor gamma transcription favored a proinflammatory M1 phenotype over an anti‐inflammatory M2 phenotype, thereby elevating hepatic inflammation. Conclusion : Suv39h2 plays a pivotal role in the regulation of inflammatory response in hepatocytes and macrophages, contributing to NASH pathogenesis. (H epatology 2017;65:1904‐1919).
A Vocation, for Love of a Mentor
Authors: Megan B. Richie
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Abstract P4-13-04: Efficacy of <i>dipsacus asperoides</i> (DA) in a model for triple negative breast cancer
Authors: NT Telang, HB Nair, GYC Wong
Journal: Cancer Research (2017)

Abstract Background: The triple negative breast cancer (TNBC) is characterized by the absence of estrogen receptor-α (ER-α), Progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER-2). This molecular subtype responds only to conventional cytotoxic chemotherapy and to small molecule based targeted therapy. These therapeutic options are associated with long-term systemic toxicity and acquired tumor resistance leading to compromised efficacy. These limitations emphasize identification of efficacious non-toxic agents for secondary prevention/therapy of TNBC. Dipsacus asperoides (DA) is a Chinese herb of a nutritional nature. The root of this herb represents an ingredient that is commonly included in the traditional Chinese herbal formulations for health management purposes. The present study examines the growth inhibitory effects of DA and identifies possible mechanistic leads for their efficacy in a preclinical cell culture model for TNBC. Experimental Model, Herbal Extract and Biomarkers: The human mammary carcinoma derived ER-α -, PR - and HER-2 - MDA-MB-231 cell linerepresents the model for TNBC. Non-fractionated aqueous extract from DA represents the test agent. Anchorage dependent growth, anchorage independent (AI) colony formation, cell cycle progression and relevant pathway specific mechanistic assays represent the quantitative biomarkers for efficacy. Results: Treatment of MDA-MB-231 cells with DA extract induces a dose dependent cytostatic growth arrest (IC50: 0.0015%, IC90: 0.0030%), and strongly inhibits AI colony formation. Within the cytostatic concentration range, DA treatment inhibits cell cycle progression via progressive G2/M arrest, suggesting abrogation of the G2/M checkpoint affecting DNA damage repair pathway. The induction of cellular apoptosis by DA is indicated by a dose dependent up-regulation of pro-apoptotic Caspase 3/7 activity. Conclusion: These data identify potential mechanistic leads for the efficacy of DA in the present model. The present study validates a mechanism based approach to prioritize efficacious non-toxic herbal extracts for secondary prevention/therapy of the TNBC molecular subtype of clinical breast cancer. Citation Format: Telang NT, Nair HB, Wong GYC. Efficacy of dipsacus asperoides (DA) in a model for triple negative breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-13-04.